Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Dexamethasone 12Gemcitabine 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Docetaxel 9venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7Methotrexate 6130-nm albumin-bound paclitaxel 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × aumolertinib × Clear all
NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Hansoh BioMedical R&D Company

Phase 2/3 Recruiting
1,080 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡